CD274 and non-small cell lung carcinoma: In the study by Strati and colleagues in HNC, patients with CTCs overexpressing PD‐L1 at the end of treatment had shorter PFS and OS.6 Similar findings were observed by Guibert et al46 in NSCLC, where PD‐L1+ CTCs were seen in all patients at progression.